The China BioMed Innovation and Investment Conference (CBIIC), as an annual grand conference to promote the communication between pharmaceutical industry and investment industry, was established and initiated by China Pharmaceutical Innovation and Research Development Association (PhIRDA) in 2016. To promote the linkage between social capital and pharmaceutical innovation and improve the innovation capability of pharmaceutical industry, the CBIIC focuses on China’s latest policies in pharmaceutical industry, explore the new trends of global pharmaceutical R&D and hot issues in investment and financing circle. The CBIIC was built as an authorized, comprehensive, professional and international high level platform for the industry leaders, experts, scholars, domestic and foreign pharmaceutical innovation enterprises and investors to learn the trend of innovation and discuss new investment channels and innovative cooperation strategies.
Established by PhIRDA, the CBIIC was successively co-hosted by Securities Association of China (SAC), China Association for Medical Devices Industry (CAMDI), Hong Kong Exchanges and Clearing Limited (HKEX) and Chinese Hospital Association (CHA), Research and Development International (RDI), iMeta Health Information Consulting Co., Ltd.(iMeta) from 2016 to 2020. By the end of 2020, the CBIIC has attracted over 12,000 participants, 4,900 domestic and foreign pharmaceutical enterprises and investment institutions. Over 500 innovative projects at home and abroad have made roadshows in these events. The One-on-One Partnering System received over 15000 meeting requests and completed1600 business negotiations. The CBIIC received extensive attention and was praised as the “most popular cooperation platform for pharmaceutical innovation and investment in Asian-Pacific region”.
To promote the in-depth cooperation between global capital and pharmaceutical innovation in the new era and new pattern, facilitate the release of vitality of pharmaceutical innovation and timely transformation of unmet clinical needs, jointly discuss the future of pharmaceutical innovation and capital, PhIRDA will host the 2021 CBIIC in Suzhou Industrial Park on September 25-27, 2021.
I. Implement the Pharmaceutical Innovative Concept and Set Various Parallel Sessions
The 2021 CBIIC will further open financing channel for pharmaceutical innovation, focus on China’s latest policies in pharmaceutical industry, explore the new trends of global pharmaceutical R&D and hot issues in investment and financing circle, share opinions on China’s latest pharmaceutical industry policies and the trend of global pharmaceutical innovation. The 2021 CBIIC will include almost 20 fascinating and excellent parallel sessions including Clinical Trial Data Release, WIT MED + Big Data, Artificial Intelligence (AI) + BioMed, and forums for Investors’ Experience Sharing, Financing M&A, Latest Drug Policy Sharing, etc. The discussions on related topics will broaden the capital connection and innovation fields, build a high-level dialogue platform for more innovative projects to seek investment and partners, enhance the core innovation capacity of China’s pharmaceutical industry, and drive domestic innovation to the global market.
II.Great Supports from National Authorized Institutions & In-depth Cooperation with Global Top Leading Organizations
The 2021 CBIIC will make further cooperation with government departments and well-known institutions around the world, and invite KOLs in pharmaceutical industry and leading experts to discuss policies and trends of global pharmaceutical innovation and financing to improve China’s capability on transformation and innovation in pharmaceutical industry.
Since its establishment, the CBIIC has received great support from prestigious institutions in China and around the world, including Chinese Academy of Medical Sciences, China Academy of Chinese Medical Sciences and authorized academic institutions; Canada, the Netherlands, Australia and other embassies and consulates in China; National Foundation for Cancer Research (NFCR), Japan Pharmaceutical Manufacturers Association (JPMA) and international organizations; Chinese Securities Association of Hong Kong (CSAHK), TMX Group Limited and global financing institutions. Moreover, J.P. Morgan supports the CBIIC as the exclusive international financial institution sponsor for several times.
III.One-on-One Partnering System Provides Close Communication between Projects and Investors
To facilitate effective communication and precise cooperation between domestic and foreign pharmaceutical innovators and investors and bridge the investment and financing, the 2021 CBIIC will continue to offer a better and more diverse platform for project presentation and communication. The One-on-One Partnering System will be provided for participants. Investors and roadshow speakers could propose an invitation in this system easily and efficiently. In this event, participants will have face-to-face communication and negotiation to seek potential opportunities and commercial values for further collaboration.
IV.Great Attention from Domestic and Global Medias and Witness the Integration of Innovation and Investment
Since 2016, the CBIIC was supported by over ten well-known magazines and traditional medias at home and abroad, including top leading international academic journal Nature, people.cn, JKB.com.cn, China Pharmaceutical News, IFNEWS.com Medicine Economic Reporter, and attracted new medias and healthcare financial medias including PharmaBoardroom, Jiemian.com, 36 Kr, Caixin Media, to make real-time report of the event and witness the integration of innovation and investment.
Under the great support of all parties, the CBIIC is gradually becoming an international, authoritative, diversified communication platform to interpret policies on drug and financing and investment circle, present pharmaceutical innovative achievements at home and abroad, lead new investment trends. As the most influential annual grand conference in Asia-Pacific region, the CBIIC will make social capital playing a leading role in the development of pharmaceutical innovation, create a more scientific and attractive investment environment and contribute to China’s economic and social development to meet the clinical needs and advance the pursuit of Healthy China.